- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | RACURA ONCOLOGY LTD: Appendix 3Y-Dr Serge Scrofani | - | ASX | ||
| Do | Racura Oncology Secures $24.38 Million from High Option Exercise Rate | 1 | Finance News Network | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Do | Thursday's HotCopper trends: Racura, Locksley, Elixir Energy, and other daily topics | 2 | The Market Online Australia | ||
| Do | Daily Special: Immutep, Bayan Mining and Minerals, Racura Oncology, Lac Gold | 2 | Finance News Network | ||
| Do | Why Chrysos, Endeavour, Racura, and Treasury Wine shares are racing higher today | 1 | The Motley Fool Australia | ||
| Do | RACURA ONCOLOGY LTD: Racura Options Raised $24.4m | - | ASX | ||
| Do | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 03.06. | RACURA ONCOLOGY LTD: Proposed issue of securities - RAC | - | ASX | ||
| 03.06. | RACURA ONCOLOGY LTD: Emerging Companies Specialist Invests in Racura | - | ASX | ||
| 01.06. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 29.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 28.05. | RACURA ONCOLOGY LTD: Proposed issue of securities - RAC | - | ASX | ||
| 28.05. | RACURA ONCOLOGY LTD: Racura Enters Underwriting Agreement for Options | - | ASX | ||
| 28.05. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 28.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 26.05. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 26.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 25.05. | Dr Boreham's Crucible: A reinvented Racura on the path to commercialisation | 1 | Stockhead | ||
| 21.05. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 21.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX |
1 2 3 4 5 Weiter >>
84 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 31,580 | +0,06 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| QIAGEN | 31,740 | -0,02 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,970 | -0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,640 | 0,00 % | Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein | DJ Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein
Von Nina Kienle
DOW JONES--Roche hat mit dem US-Biotechunternehmen Nurix Therapeutics eine exklusive Lizenz- und Kooperationsvereinbarung... ► Artikel lesen | |
| VERA THERAPEUTICS | 31,810 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| ERASCA | 13,400 | -0,07 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,285 | -0,04 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| MINERALYS THERAPEUTICS | 24,210 | +0,12 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 41,240 | -0,02 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity | ||
| ENLIVEN THERAPEUTICS | 36,125 | +0,04 % | Stifel initiates Enliven Therapeutics stock with buy rating | ||
| CG ONCOLOGY | 56,69 | +0,04 % | CG Oncology, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 250,20 | -0,05 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCUTIS BIOTHERAPEUTICS | 22,770 | -0,09 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDGEWISE THERAPEUTICS | 34,080 | +0,06 % | Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal | ||
| RELAY THERAPEUTICS | 14,085 | -0,04 % | Relay Therapeutics Shares Jump 18% |
RACURA ONCOLOGY LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -7,32 % bei einem Aktienkurs von 1,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.